Form 8-K - Current report:
SEC Accession No. 0001140361-25-020353
Filing Date
2025-05-23
Accepted
2025-05-23 16:46:36
Documents
15
Period of Report
2025-05-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20049643_8k.htm   iXBRL 8-K 37374
2 EXHIBIT 1.1 ef20049643_ex1-1.htm EX-1.1 323822
3 EXHIBIT 5.1 ef20049643_ex5-1.htm EX-5.1 7497
7 image0.jpg GRAPHIC 120814
  Complete submission text file 0001140361-25-020353.txt   741470

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA gyre-20250522.xsd EX-101.SCH 4024
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE gyre-20250522_lab.xml EX-101.LAB 21966
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gyre-20250522_pre.xml EX-101.PRE 16072
18 EXTRACTED XBRL INSTANCE DOCUMENT ef20049643_8k_htm.xml XML 4205
Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51173 | Film No.: 25983092
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)